Keros Therapeutics (KROS) Non Operating Income (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Non Operating Income came in at $4.3 million in Q4 2025, down 42.95% YoY from $7.5 million in Q4 2024, and down 35.7% on a QoQ basis from $6.7 million in Q3 2025.
Keros Therapeutics (KROS) Non Operating Income (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Non Operating Income data on file, last reported at $4.3 million in Q4 2025.
- Quarterly Non Operating Income fell 42.95% year-over-year to $4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.3 million (up 2.3% YoY) and the FY2025 annual result came in at $24.3 million, up 2.3% from the prior year.
- Non Operating Income slipped to $4.3 million in Q4 2025, from $6.7 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $7.5 million in Q4 2024 to a low of -$138000.0 in Q3 2021.
- A 5-year average of $3.7 million and a median of $4.1 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2021 — Non Operating Income slumped 151.59% — and 2023, when it surged 5208.33%.
- Tracing KROS's Non Operating Income over 5 years: stood at -$75000.0 in 2021, then jumped by 3089.33% to $2.2 million in 2022, then surged by 177.07% to $6.2 million in 2023, then increased by 21.18% to $7.5 million in 2024, then plunged by 42.95% to $4.3 million in 2025.
- The last three Non Operating Income figures came in at $4.3 million (Q4 2025), $6.7 million (Q3 2025), and $6.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.23 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | 6.68 Mn |
| Jun 30, 2025 | 6.90 Mn |
| Mar 31, 2025 | 6.45 Mn |
| Dec 31, 2024 | 7.53 Mn |
| Sep 30, 2024 | 5.70 Mn |
| Jun 30, 2024 | 5.18 Mn |
| Mar 31, 2024 | 5.37 Mn |
| Dec 31, 2023 | 6.21 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Mar 31, 2023 | 3.07 Mn |
| Dec 31, 2022 | 2.24 Mn |
| Sep 30, 2022 | 4.47 Mn |
| Jun 30, 2022 | 3.46 Mn |
| Mar 31, 2022 | -60,000.00 |
| Dec 31, 2021 | -75,000.00 |
| Sep 30, 2021 | -138,000.00 |
| Jun 30, 2021 | -81,000.00 |